1. Mitigating the Effects of Nonadherence in Clinical Trials.

    The Journal of clinical pharmacology and new drugs 56(9):1151 (2016) PMID 26634893

    Accounting for subject nonadherence and eliminating inappropriate subjects in clinical trials are critical elements of a successful study. Nonadherence can increase variance, lower study power, and reduce the magnitude of treatment effects. Inappropriate subjects (including those who do not have...
  2. Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.

    Nature Reviews: Drug Discovery 15(7):516 (2016) PMID 27312728

  3. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.

    Drug and Alcohol Dependence 158:1 (2016) PMID 26652899 PMCID PMC4698050

    The development and approval of an efficacious pharmacotherapy for stimulant use disorders has been limited by the lack of a meaningful indicator of treatment success, other than sustained abstinence. In March, 2015, a meeting sponsored by Analgesic, Anesthetic, and Addiction Clinical Trial Tran...
  4. Biologic Approaches to Treat Substance-Use Disorders.

    Trends in Pharmacological Sciences 36(10):628 (2015) PMID 26435208 PMCID PMC4593975

    In contrast to traditional pharmacodynamic approaches to treat substance-use disorders (SUDs), the use of biologics (vaccines, monoclonal antibodies, and genetically modified enzymes) is based on a pharmacokinetic principle: reduce the amount of (and, ideally, eliminate) abused drug entering the...
  5. Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test.

    Acta Neuropsychiatrica 27(4):228 (2015) PMID 25858023

    The N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine, produces rapid and enduring antidepressant effect in patients with treatment-resistant depression. Similar dramatic effects have not been observed in clinical trials with other NMDAR antagonists indicating ketamine may possess unique...
  6. Trends in Opioid Analgesic Abuse and Mortality in the United States

    New England Journal of Medicine 372(16):1572 (2015) PMID 25875268

    To the Editor: Dart et al. (Jan. 15 issue)1 conclude that the United States may be making progress in controlling the abuse of opioid analgesics. However, they understate the increasing problem of opioid-associated deaths, especially those related to heroin. First, the death ...
  7. Trends in opioid analgesic abuse and mortality in the United States.

    New England Journal of Medicine 372(16):1572 (2015) PMID 25875269

  8. 1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.

    Psychopharmacology 232(6):1025 (2015) PMID 25260339 PMCID PMC4336651

    In addition to the negative and positive symptoms of schizophrenia, cognitive deficits, including prefrontal cortical dysfunction, are now recognized as core features of this disorder. Compounds increasing the NMDA receptor function via the strychnine-insensitive glycine receptors have been prop...
  9. Synopsis of Expert Opinions and Conclusions.

    CNS and Neurological Disorders 14(6):773 (2015) PMID 26073938

  10. Editorial: Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of Constrained Resources?

    CNS and Neurological Disorders 14(6):691 (2015) PMID 26073937

  11. Harry L June.

    PMID 25381711 PMCID PMC4229593

  12. Translational potential of naloxone and naltrexone as TLR4 antagonists.

    Trends in Pharmacological Sciences 35(9):431 (2014) PMID 25109569

  13. Therapeutic doses of buspirone block D3 receptors in the living primate brain.

    International Journal of Neuropsychopharmacology 17(8):1257 (2014) PMID 24679922

    Dopamine D3 receptor (D3R) antagonists may be effective medications for multiple substance use disorders (SUDs). However, no selective D3R antagonists are currently available for clinical testing. Buspirone, originally characterized as a 5-HT1A partial agonist and used as an anxiolytic, also bin...
  14. Glutamate-based antidepressants: preclinical psychopharmacology.

    Biological Psychiatry 73(12):1125 (2013) PMID 23453290

    Over the past 20 years, converging lines of evidence have both linked glutamatergic dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic synapse presents multiple targets for developing novel antidepressants. The robust antidepressant effects of the N-methyl-D...
  15. Response to W. Sieghart.

    Trends in Pharmacological Sciences 34(3):146 (2013) PMID 23384390

  16. Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

    International Journal of Neuropsychopharmacology 16(2):445 (2013) PMID 22827916

    Converging lines of evidence indicate that elevations in synaptic dopamine levels play a pivotal role in the reinforcing effects of cocaine, which are associated with its abuse liability. This evidence has led to the exploration of dopamine receptor blockers as pharmacotherapy for cocaine addict...
  17. Addiction therapeutics: obstacles and opportunities.

    Biological Psychiatry 72(11):890 (2012) PMID 23121867 PMCID PMC4828659

  18. Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology.

    Pharmacology Biochemistry and Behavior 103(1):111 (2012) PMID 22884707 PMCID PMC3537915

    The co-occurrence of alcoholism and depression is highly prevalent and difficult to treat. In an animal model of binge drinking that exhibits abstinence-induced behaviors reminiscent of negative affective states, the triple monoamine uptake inhibitor, amitifadine, produced a selective, dose depe...
  19. Anxioselective anxiolytics: on a quest for the Holy Grail.

    Trends in Pharmacological Sciences 33(11):611 (2012) PMID 22981367 PMCID PMC3482271

    The discovery of benzodiazepine receptors provided the impetus to discover and develop anxioselective anxiolytics ('Valium without the side effects'). The market potential for an anxioselective based on the γ-aminobutyric acid A (GABA(A)) receptor resulted in clinical trials of multiple compound...
  20. Medication discovery for addiction: translating the dopamine D3 receptor hypothesis.

    Biochemical Pharmacology 84(7):882 (2012) PMID 22781742 PMCID PMC3836213

    The dopamine D3 receptor (D3R) has been investigated as a potential target for medication development to treat substance use disorders (SUDs) with a particular focus on cocaine and methamphetamine. Currently, there are no approved medications to treat cocaine and methamphetamine addiction and th...